Skip to content
stocks-llm

AKTIS ONCOLOGY INC (AKTS)

Health Care · biotechnology / radiopharmaceuticals · NASDAQ

Aktis Oncology is developing a pipeline of precision radiopharmaceuticals designed to deliver potent cancer-killing radiation directly to tumors.

View SEC filings Filings archive → Large price moves → Website Find companies like AKTS → Ask about AKTS →

What AKTIS ONCOLOGY INC does

Aktis Oncology is a biotechnology company focused on developing novel targeted radiopharmaceuticals for the treatment of cancer. The company utilizes a proprietary technology platform to design precision therapies that deliver therapeutic radioisotopes directly to tumor cells.

Themes: oncology, radiopharmaceuticals, precision medicine

Fundamentals

  • Price$16.08 as of 2026-10-20 close
  • Market cap$859M as of 2026-06-30 (share count; price 2026-10-20)
  • P/En/a earnings data not available
  • ROICn/a No figure: its 10-K tags no operating income.
  • Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
  • Beta1.71 as of 2026-09-03
  • Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)

Ask why AKTS looks like this →

Quarterly results

Balance sheet at 2026-06-30

  • Cash and equivalents$82M
  • Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt

From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.

Ask how AKTS's latest quarter compares →

Analyst consensus

  • Consensus ratingStrong Buy (1.10 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
  • Mean price target$35.39 range $31.50 – $40.00; median $35.00

Analyst estimates, as of 2026-10-20. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.

Analyst EPS estimate for AKTS

  • Consensus EPS estimate-$0.4537 next reporting period, as of 2026-10-20
  • Estimate change, 30 days+$0.00429 from -$0.458, on 2026-09-20, 30-day window
  • Readings revised upward20% of 10 comparable readings

The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.

Ask how AKTS's estimates have moved →

Key risks (from latest filing)

["Significant history of losses and expected future losses, with no assurance of achieving or maintaining profitability.","Dependence on successful clinical trials, which are subject to substantial risk of failure or delay.","Reliance on collaborations and potential inability to secure future funding or maintain existing partnerships."]

See AKTS's biggest risks from its latest 10-Q →

What changed in the latest 10-Q

AI-assisted comparison of AKTS's 10-Q filed 2026-08-13 against the prior one filed 2026-05-11.

Management's Discussion & Analysis (MD&A)

  • Added:
    • In the newer filing (2026-08-13), the phrase 'the "Quarterly Report"' is added as a defined term reference: 'this Quarterly Report on Form 10-Q (the "Quarterly Report") and our Annual Report on Form 10-K...'
    • In the newer filing (2026-08-13), accumulated deficit is stated as $199.0 million as of June 30, 2026.
    • In the newer filing (2026-08-13), net losses are stated as $42.5 million and $33.1 million for the six months ended June 30, 2026 and 2025, respectively.
  • Removed:
    • In the older filing (2026-05-11), accumulated deficit is stated as $174.9 million as of March 31, 2026.
    • In the older filing (2026-05-11), net losses are stated as $18.3 million and $15.0 million for the three months ended March 31, 2026 and 2025, respectively.
  • Reworded:
    • Older filing (2026-05-11) says 'filed with the Securities and Exchange Commission ("SEC") on March 30, 2026' while newer filing (2026-08-13) says 'filed with the Securities and Exchange Commission (the "SEC") on March 30, 2026' (parenthetical changed from quoted to unquoted 'the').
    • Older filing (2026-05-11) says 'elsewhere in this Quarterly Report on Form 10-Q' in the risk factors reference, while newer filing (2026-08-13) says 'elsewhere in this Quarterly Report'.
    • Older filing (2026-05-11) says 'the "Risk Factor" section of our Annual Report -K' while newer filing (2026-08-13) says 'the "Risk Factors" section of our Annual Report' (singular to plural and removal of '-K').
    • Older filing (2026-05-11) says 'quality of life benefits can be conferred' while newer filing (2026-08-13) says 'quality-of-life benefits can be conferred' (hyphenation change).
    • Older filing (2026-05-11) says 'prostate specific membrane antigen' while newer filing (2026-08-13) says 'prostate-specific membrane antigen' (hyphenation change).
    • Older filing (2026-05-11) says 'funded our operations primarily with proceeds the issuance and sale' while newer filing (2026-08-13) says 'funded our operations primarily with proceeds from the issuance and sale' (added 'from').
    • Older filing (2026-05-11) says 'other offering expenses incurred through March 31, 2026' while newer filing (2026-08-13) says 'other offering expenses' (removed 'incurred through March 31, 2026').
    • Older filing (2026-05-11) bullet says 'advance our lead product candidate, [ 225 Ac]Ac-AKY-1189 for Nectin-4 expressing tumors, through clinical trials' while newer filing (2026-08-13) bullet says 'advance [ 225 Ac]Ac-AKY-1189 for Nectin-4 expressing tumors and [ 225 Ac]Ac-AKY-2519 for B7-H3 expressing tumors through clinical trials'.
    • Older filing (2026-05-11) has a separate bullet 'commence clinical trials for [ 225 Ac]Ac-AKY-2519 for B7-H3 expressing tumors' while newer filing (2026-08-13) has no separate 'commence clinical trials' bullet and instead combines this into the preceding bullet.
    • Older filing (2026-05-11) bullet says 'continue IND-enabling preclinical studies' while newer filing (2026-08-13) bullet says 'continue investigational new drug, or IND, -enabling preclinical studies' (added 'investigational new drug, or IND,' phrasing).
    • Older filing (2026-05-11) final paragraph ends with 'collaborations, licenses or other strategic arra' while newer filing (2026-08-13) ends with 'collaborations, licenses or other strategic arrangements' (different truncation point of the source text).
    • Older filing (2026-05-11) reports quarterly financial figures (three months ended March 31, 2026 and 2025), while newer filing (2026-08-13) reports six-month financial figures (six months ended June 30, 2026 and 2025).
  • Notes:
    • The newer filing text appears to be truncated at 'See "— Liquidity and capital' and the older filing at 'collaborations, licenses or other strategic arra', so differences beyond those truncation points cannot be assessed.
    • Differences in financial figures (accumulated deficit and net losses) reflect different reporting periods (March 31 vs June 30 and three-month vs six-month) rather than necessarily indicating a correction or restatement of the same period.

AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.

Ask what changed in AKTS's latest 10-Q →

Insider activity (SEC Form 4)

0 open-market purchases and 2 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 6 days since 2026-10-16 have not been checked yet.

  • Last 30 days · read to 2026-10-160 buys · 2 sells ($258621) — 1 selling insider
  • Last 90 days · read to 2026-10-160 buys · 2 sells ($258621) — 1 selling insider
  • Last 180 days · read to 2026-10-160 buys · 11 sells ($3M) — 3 selling insiders

Cluster buying: 6 different insiders reported open-market purchases (SEC code P) of AKTS within a 30-day window between 2026-01-12 and 2026-01-12. Disclosed Form 4 activity, not a prediction of performance or a buy signal.

Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)

Most recent open-market transaction: 2026-09-23. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.

View full insider trading history → View SEC Form 3/4/5 filings

Ask about AKTS's insider activity →

Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.

Institutional ownership (13F)

5 institutional 13F filers reported holding AKTS as of 2026-06-30 (quarter-end position, filed within 45 days).

  • Distinct 13F filers 5
  • Reported shares held 3,194,473
  • Reported value $102,957,866

reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".

Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.

Ask about AKTS's institutional holders → See what each manager we track holds →

Short interest (FINRA)

AKTS had 4,715,294 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).

AKTS had 8.82% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.3 days to cover at the same settlement.

  • Reported short interest (shares) 4,715,294
  • Short interest (% of shares outstanding) 8.82%
  • Prior settlement (shares) 3,252,475
  • Reported change 44.98%
  • Days to cover (reported) 7.3

Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.

Ask about AKTS's short interest →

Competitors & peers

AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.

Not quite? Describe exactly what you want →

Compare AKTS vs…

AKTIS ONCOLOGY INC is found in…

Frequently asked questions

What does AKTIS ONCOLOGY INC (AKTS) do?

Aktis Oncology is a biotechnology company focused on developing novel targeted radiopharmaceuticals for the treatment of cancer. The company utilizes a proprietary technology platform to design precision therapies that deliver therapeutic radioisotopes directly to tumor cells.

What sector is AKTIS ONCOLOGY INC (AKTS) in?

AKTIS ONCOLOGY INC (AKTS) is classified in the Health Care sector. Its industry is biotechnology / radiopharmaceuticals. It trades on NASDAQ.

Who are AKTIS ONCOLOGY INC's (AKTS) competitors?

Notable peers of AKTIS ONCOLOGY INC (AKTS) include Novartis, Bayer, Eli Lilly, RayzeBio (acquired by Bristol Myers Squibb) and Point Biopharma (acquired by Eli Lilly). This peer set is informational only — not financial advice.

Where does stocks-llm's data on AKTS come from?

Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.

Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-10-20.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.